HTG Molecular Diagnostics Ownership 2024 | Who Owns HTG Molecular Diagnostics Now?
Institutional Ownership
0.00%
Insider Ownership
6.54%
Retail Ownership
93.46%
Institutional Holders
1.00
HTG Molecular Diagnostics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 1.65% | - | 14,692 | 14,692 | 100.00% | 39,668,000 | Mar 31, 2023 |
UBS GROUP AG | 0.58% | - | 5,198 | 3,223 | 163.19% | 14,034,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.17% | 0.00% | 1,481 | -5,208 | -77.86% | 4,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.14% | - | 1,289 | -4,815 | -78.88% | 3,480,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.10% | - | 884 | - | - | 2,387,000 | Mar 31, 2023 |
HIGHMARK WEALTH MANAGEMENT LLC | 0.07% | 0.00% | 580 | - | - | 1,566,000 | Mar 31, 2023 |
NORDWAND ADVISORS, LLC | 0.06% | 0.00% | 500 | 500 | 100.00% | 1,350,000 | Mar 31, 2023 |
ALLWORTH FINANCIAL LP | 0.03% | - | 279 | 2 | 0.72% | 754,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 13 | 9 | 225.00% | 35,000 | Mar 31, 2023 |
TCI WEALTH ADVISORS, INC. | 0.00% | - | 2 | - | - | 6,000 | Mar 31, 2023 |
HTG Molecular Diagnostics's largest institutional shareholder is VANGUARD GROUP INC, holding 1.65% of the company's total share outstanding, currently valued at $39.67M. The top 10 institutional shareholders own together 2.80% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HIGHMARK WEALTH MANAGEMENT LLC | 0.07% | 0.00% | 580 | - | - | 1,566,000 | Mar 31, 2023 |
NORDWAND ADVISORS, LLC | 0.06% | 0.00% | 500 | 500 | 100.00% | 1,350,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.17% | 0.00% | 1,481 | -5,208 | -77.86% | 4,000 | Mar 31, 2023 |
ALLWORTH FINANCIAL LP | 0.03% | - | 279 | 2 | 0.72% | 754,000 | Mar 31, 2023 |
UBS GROUP AG | 0.58% | - | 5,198 | 3,223 | 163.19% | 14,034,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 1.65% | - | 14,692 | 14,692 | 100.00% | 39,668,000 | Mar 31, 2023 |
TCI WEALTH ADVISORS, INC. | 0.00% | - | 2 | - | - | 6,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.10% | - | 884 | - | - | 2,387,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.14% | - | 1,289 | -4,815 | -78.88% | 3,480,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 13 | 9 | 225.00% | 35,000 | Mar 31, 2023 |
The largest HTG Molecular Diagnostics shareholder by % of total assets is HIGHMARK WEALTH MANAGEMENT LLC. The company owns 580.00 shares of HTG Molecular Diagnostics (HTGM), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 1.65% | - | 14,692 | 14,692 | 100.00% | 39,668,000 | Mar 31, 2023 |
UBS GROUP AG | 0.58% | - | 5,198 | 3,223 | 163.19% | 14,034,000 | Mar 31, 2023 |
NORDWAND ADVISORS, LLC | 0.06% | 0.00% | 500 | 500 | 100.00% | 1,350,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 13 | 9 | 225.00% | 35,000 | Mar 31, 2023 |
ALLWORTH FINANCIAL LP | 0.03% | - | 279 | 2 | 0.72% | 754,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.10% | - | 884 | - | - | 2,387,000 | Mar 31, 2023 |
TCI WEALTH ADVISORS, INC. | 0.00% | - | 2 | - | - | 6,000 | Mar 31, 2023 |
HIGHMARK WEALTH MANAGEMENT LLC | 0.07% | 0.00% | 580 | - | - | 1,566,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.14% | - | 1,289 | -4,815 | -78.88% | 3,480,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.17% | 0.00% | 1,481 | -5,208 | -77.86% | 4,000 | Mar 31, 2023 |
As of Mar 31 2023, HTG Molecular Diagnostics's largest institutional buyer is VANGUARD GROUP INC. The company purchased 14.69K stocks of HTGM, valued at $39.67M.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
TOWER RESEARCH CAPITAL LLC (TRC) | 0.17% | 0.00% | 1,481 | -5,208 | -77.86% | 4,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.14% | - | 1,289 | -4,815 | -78.88% | 3,480,000 | Mar 31, 2023 |
HIGHMARK WEALTH MANAGEMENT LLC | 0.07% | 0.00% | 580 | - | - | 1,566,000 | Mar 31, 2023 |
TCI WEALTH ADVISORS, INC. | 0.00% | - | 2 | - | - | 6,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.10% | - | 884 | - | - | 2,387,000 | Mar 31, 2023 |
ALLWORTH FINANCIAL LP | 0.03% | - | 279 | 2 | 0.72% | 754,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 13 | 9 | 225.00% | 35,000 | Mar 31, 2023 |
NORDWAND ADVISORS, LLC | 0.06% | 0.00% | 500 | 500 | 100.00% | 1,350,000 | Mar 31, 2023 |
UBS GROUP AG | 0.58% | - | 5,198 | 3,223 | 163.19% | 14,034,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 1.65% | - | 14,692 | 14,692 | 100.00% | 39,668,000 | Mar 31, 2023 |
As of Mar 31 2023, HTG Molecular Diagnostics's biggest institutional seller is TOWER RESEARCH CAPITAL LLC (TRC). The company sold -5.21K shares of HTGM, valued at $4.00K.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 1.65% | - | 14,692 | 14,692 | 100.00% | 39,668,000 | Mar 31, 2023 |
NORDWAND ADVISORS, LLC | 0.06% | 0.00% | 500 | 500 | 100.00% | 1,350,000 | Mar 31, 2023 |
HTG Molecular Diagnostics's largest new institutional shareholder by number of shares is VANGUARD GROUP INC, purchased 14.69K shares, valued at $39.67M, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
HTG Molecular Diagnostics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
T. Rowe Price Health Sciences Fund, Inc. | 0.30% | 989,073 | - | - | Mar 31, 2024 |
T. Rowe Price Equity Series, Inc. | 0.04% | 66,512 | - | - | Mar 31, 2024 |
FIDELITY SELECT PORTFOLIOS | 0.03% | 1,826,043 | - | - | Feb 29, 2024 |
World Funds Trust | 0.01% | 62,500 | - | - | Jan 31, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 1,403,374 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 377,821 | - | - | Feb 29, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 30,070 | - | - | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 18,640 | - | - | Feb 29, 2024 |
VALIC Co I | 0.00% | 91,620 | - | - | Feb 29, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 9,888 | - | - | Jan 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 34,686 | - | - | Mar 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 439 | - | - | Mar 31, 2024 |
HTG Molecular Diagnostics's largest mutual fund holder by % of total assets is "T. Rowe Price Health Sciences Fund, Inc.", owning 989.07K shares, compromising 0.30% of its total assets.
HTG Molecular Diagnostics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Mar, 21 | 1 | - |
31 Dec, 20 | 1 | -96.15% |
30 Sep, 20 | 26 | - |
30 Jun, 20 | 26 | -13.33% |
31 Mar, 20 | 30 | 11.11% |
31 Dec, 19 | 27 | -34.15% |
30 Sep, 19 | 41 | -2.38% |
30 Jun, 19 | 42 | 10.53% |
31 Mar, 19 | 38 | -19.15% |
31 Dec, 18 | 47 | -12.96% |
30 Sep, 18 | 54 | 28.57% |
30 Jun, 18 | 42 | 7.69% |
31 Mar, 18 | 39 | 143.75% |
31 Dec, 17 | 16 | -20.00% |
30 Sep, 17 | 20 | 11.11% |
30 Jun, 17 | 18 | -10.00% |
31 Mar, 17 | 20 | 66.67% |
31 Dec, 16 | 12 | -45.45% |
30 Sep, 16 | 22 | - |
30 Jun, 16 | 22 | 10.00% |
31 Mar, 16 | 20 | 5.26% |
31 Dec, 15 | 19 | -13.64% |
30 Sep, 15 | 22 | - |
30 Jun, 15 | 22 | - |
As of 31 Mar 21, 1 institutions are holding HTG Molecular Diagnostics's shares, representing an increase of 0.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Mar, 21 | 466 | - |
31 Dec, 20 | 466 | -100.00% |
30 Sep, 20 | 15,478,134 | 12.29% |
30 Jun, 20 | 13,783,735 | -22.62% |
31 Mar, 20 | 17,812,426 | -6.18% |
31 Dec, 19 | 18,985,882 | -15.20% |
30 Sep, 19 | 22,389,382 | 73.27% |
30 Jun, 19 | 12,921,473 | 0.04% |
31 Mar, 19 | 12,915,872 | -11.16% |
31 Dec, 18 | 14,537,695 | 9.72% |
30 Sep, 18 | 13,249,829 | -4.99% |
30 Jun, 18 | 13,946,022 | 24.98% |
31 Mar, 18 | 11,158,824 | 445.75% |
31 Dec, 17 | 2,044,669 | 8.73% |
30 Sep, 17 | 1,880,489 | -24.16% |
30 Jun, 17 | 2,479,616 | -16.88% |
31 Mar, 17 | 2,983,120 | 3.30% |
31 Dec, 16 | 2,887,834 | -13.50% |
30 Sep, 16 | 3,338,475 | -1.84% |
30 Jun, 16 | 3,401,108 | -2.87% |
31 Mar, 16 | 3,501,461 | -4.85% |
31 Dec, 15 | 3,680,034 | -53.64% |
30 Sep, 15 | 7,938,570 | 114.84% |
30 Jun, 15 | 3,695,159 | - |
HTG Molecular Diagnostics (HTGM) has 466.00 shares outstanding as of 31 Mar 21, up 0.00% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Mar, 21 | 0.00% | 1000000.00% |
31 Dec, 20 | 0.00% | 0.27% |
30 Sep, 20 | 0.15% | 701.24% |
30 Jun, 20 | 0.15% | 396.56% |
31 Mar, 20 | 0.19% | 459.45% |
31 Dec, 19 | 0.20% | 352.16% |
30 Sep, 19 | 0.24% | 1246.55% |
30 Jun, 19 | 0.14% | 720.23% |
31 Mar, 19 | 0.14% | 568.03% |
31 Dec, 18 | 0.16% | 769.96% |
30 Sep, 18 | 0.14% | 633.40% |
30 Jun, 18 | 0.15% | 1041.50% |
31 Mar, 18 | 0.12% | 24806.82% |
31 Dec, 17 | 0.02% | 5382.67% |
30 Sep, 17 | 0.02% | 2840.45% |
30 Jun, 17 | 0.03% | 2589.41% |
31 Mar, 17 | 0.03% | 3321.54% |
31 Dec, 16 | 0.03% | 2409.47% |
30 Sep, 16 | 0.04% | 2681.97% |
30 Jun, 16 | 0.04% | 2576.39% |
31 Mar, 16 | 0.04% | 2402.78% |
31 Dec, 15 | 0.04% | 542.86% |
30 Sep, 15 | 0.09% | 5411.59% |
30 Jun, 15 | 0.04% | - |
As of 31 Mar 21, HTG Molecular Diagnostics is held by 0.00% institutional shareholders, representing a 1000000.00% growth compared to 31 Dec 20.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Mar, 21 | - | - |
31 Dec, 20 | - | -100.00% |
30 Sep, 20 | 13 | -18.75% |
30 Jun, 20 | 16 | - |
31 Mar, 20 | 16 | 14.29% |
31 Dec, 19 | 14 | -39.13% |
30 Sep, 19 | 23 | 21.05% |
30 Jun, 19 | 19 | 18.75% |
31 Mar, 19 | 16 | -42.86% |
31 Dec, 18 | 28 | -15.15% |
30 Sep, 18 | 33 | 26.92% |
30 Jun, 18 | 26 | -21.21% |
31 Mar, 18 | 33 | 312.50% |
31 Dec, 17 | 8 | -42.86% |
30 Sep, 17 | 14 | 55.56% |
30 Jun, 17 | 9 | -10.00% |
31 Mar, 17 | 10 | 100.00% |
31 Dec, 16 | 5 | - |
30 Sep, 16 | 5 | -28.57% |
30 Jun, 16 | 7 | 75.00% |
31 Mar, 16 | 4 | -20.00% |
31 Dec, 15 | 5 | -54.55% |
30 Sep, 15 | 11 | -50.00% |
30 Jun, 15 | 22 | - |
- institutional shareholders have increased their position in HTGM stock as of 31 Mar 21 compared to - in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Mar, 21 | - | -100.00% |
31 Dec, 20 | 1 | -80.00% |
30 Sep, 20 | 5 | 66.67% |
30 Jun, 20 | 3 | -57.14% |
31 Mar, 20 | 7 | 16.67% |
31 Dec, 19 | 6 | -33.33% |
30 Sep, 19 | 9 | -35.71% |
30 Jun, 19 | 14 | - |
31 Mar, 19 | 14 | 40.00% |
31 Dec, 18 | 10 | -16.67% |
30 Sep, 18 | 12 | 71.43% |
30 Jun, 18 | 7 | - |
31 Mar, 18 | - | -100.00% |
31 Dec, 17 | 2 | - |
30 Sep, 17 | 2 | -33.33% |
30 Jun, 17 | 3 | - |
31 Mar, 17 | 3 | 200.00% |
31 Dec, 16 | 1 | -88.89% |
30 Sep, 16 | 9 | 50.00% |
30 Jun, 16 | 6 | -33.33% |
31 Mar, 16 | 9 | 200.00% |
31 Dec, 15 | 3 | 200.00% |
30 Sep, 15 | 1 | - |
30 Jun, 15 | - | - |
- institutional shareholders have reduced their position in HTGM stock as of 31 Mar 21 compared to 1 in the previous quarter (a -100.00% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar, 21 | 1 | - | 466 | - | 0.00% | 1000000.00% | - | - | - | -100.00% |
31 Dec, 20 | 1 | -96.15% | 466 | -100.00% | 0.00% | 0.27% | - | -100.00% | 1 | -80.00% |
30 Sep, 20 | 26 | - | 15,478,134 | 12.29% | 0.15% | 701.24% | 13 | -18.75% | 5 | 66.67% |
30 Jun, 20 | 26 | -13.33% | 13,783,735 | -22.62% | 0.15% | 396.56% | 16 | - | 3 | -57.14% |
31 Mar, 20 | 30 | 11.11% | 17,812,426 | -6.18% | 0.19% | 459.45% | 16 | 14.29% | 7 | 16.67% |
31 Dec, 19 | 27 | -34.15% | 18,985,882 | -15.20% | 0.20% | 352.16% | 14 | -39.13% | 6 | -33.33% |
30 Sep, 19 | 41 | -2.38% | 22,389,382 | 73.27% | 0.24% | 1246.55% | 23 | 21.05% | 9 | -35.71% |
30 Jun, 19 | 42 | 10.53% | 12,921,473 | 0.04% | 0.14% | 720.23% | 19 | 18.75% | 14 | - |
31 Mar, 19 | 38 | -19.15% | 12,915,872 | -11.16% | 0.14% | 568.03% | 16 | -42.86% | 14 | 40.00% |
31 Dec, 18 | 47 | -12.96% | 14,537,695 | 9.72% | 0.16% | 769.96% | 28 | -15.15% | 10 | -16.67% |
30 Sep, 18 | 54 | 28.57% | 13,249,829 | -4.99% | 0.14% | 633.40% | 33 | 26.92% | 12 | 71.43% |
30 Jun, 18 | 42 | 7.69% | 13,946,022 | 24.98% | 0.15% | 1041.50% | 26 | -21.21% | 7 | - |
31 Mar, 18 | 39 | 143.75% | 11,158,824 | 445.75% | 0.12% | 24806.82% | 33 | 312.50% | - | -100.00% |
31 Dec, 17 | 16 | -20.00% | 2,044,669 | 8.73% | 0.02% | 5382.67% | 8 | -42.86% | 2 | - |
30 Sep, 17 | 20 | 11.11% | 1,880,489 | -24.16% | 0.02% | 2840.45% | 14 | 55.56% | 2 | -33.33% |
30 Jun, 17 | 18 | -10.00% | 2,479,616 | -16.88% | 0.03% | 2589.41% | 9 | -10.00% | 3 | - |
31 Mar, 17 | 20 | 66.67% | 2,983,120 | 3.30% | 0.03% | 3321.54% | 10 | 100.00% | 3 | 200.00% |
31 Dec, 16 | 12 | -45.45% | 2,887,834 | -13.50% | 0.03% | 2409.47% | 5 | - | 1 | -88.89% |
30 Sep, 16 | 22 | - | 3,338,475 | -1.84% | 0.04% | 2681.97% | 5 | -28.57% | 9 | 50.00% |
30 Jun, 16 | 22 | 10.00% | 3,401,108 | -2.87% | 0.04% | 2576.39% | 7 | 75.00% | 6 | -33.33% |
31 Mar, 16 | 20 | 5.26% | 3,501,461 | -4.85% | 0.04% | 2402.78% | 4 | -20.00% | 9 | 200.00% |
31 Dec, 15 | 19 | -13.64% | 3,680,034 | -53.64% | 0.04% | 542.86% | 5 | -54.55% | 3 | 200.00% |
30 Sep, 15 | 22 | - | 7,938,570 | 114.84% | 0.09% | 5411.59% | 11 | -50.00% | 1 | - |
30 Jun, 15 | 22 | - | 3,695,159 | - | 0.04% | - | 22 | - | - | - |
HTG Molecular Diagnostics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of HTG Molecular Diagnostics's stock was made by Barat Stephen on Jun 09 2023, selling 888 shares at $0.80 per share (valued at $710.40).
HTG Molecular Diagnostics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2023 | - | 1 | - |
Q1 2023 | - | 4 | - |
Q4 2022 | 4 | - | - |
Q3 2022 | 10 | 1 | 1000.00% |
Q2 2022 | 4 | 3 | 133.33% |
Q1 2022 | 1 | 3 | 33.33% |
Q4 2021 | 4 | 3 | 133.33% |
Q3 2021 | 6 | 3 | 200.00% |
Q2 2021 | 4 | 3 | 133.33% |
Q1 2021 | - | 3 | - |
Q4 2020 | 5 | 4 | 125.00% |
Q3 2020 | 11 | 4 | 275.00% |
Q2 2020 | 5 | 4 | 125.00% |
Q1 2020 | 6 | 17 | 35.29% |
Q4 2019 | 5 | 4 | 125.00% |
Q3 2019 | 17 | 7 | 242.86% |
Q2 2019 | 6 | 11 | 54.55% |
Q4 2018 | 3 | 6 | 50.00% |
Q3 2018 | 18 | - | - |
Q2 2018 | 4 | - | - |
0 total buy trades, and 1 total sell trades (buy/sell ratio of 0.00%) were made by HTG Molecular Diagnostics's insiders, as of Q2 2023.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2023 | - | 1 | - |
Q1 2023 | - | - | - |
Q4 2022 | - | - | - |
Q3 2022 | - | - | - |
Q2 2022 | - | - | - |
Q1 2022 | - | - | - |
Q4 2021 | - | - | - |
Q3 2021 | - | - | - |
Q2 2021 | - | - | - |
Q1 2021 | - | - | - |
Q4 2020 | - | - | - |
Q3 2020 | - | - | - |
Q2 2020 | - | - | - |
Q1 2020 | 2 | - | - |
Q4 2019 | - | 1 | - |
Q3 2019 | - | - | - |
Q2 2019 | - | - | - |
Q4 2018 | - | - | - |
Q3 2018 | - | - | - |
Q2 2018 | - | - | - |
As of Q2 2023, Insider owners conducted 0 open market buy trades and 1 open market sell trades of HTG Molecular Diagnostics's stocks.
HTGM Ownership FAQ
Who Owns HTG Molecular Diagnostics?
HTG Molecular Diagnostics is owned by institutional shareholders (0.00%), insiders (6.54%), and public (93.46%). The largest institutional shareholder of HTG Molecular Diagnostics is VANGUARD GROUP INC (1.65% of total shares) and the top mutual fund owner is T. Rowe Price Health Sciences Fund, Inc. (0.30% of total shares).
Who are the major institutional shareholders of HTG Molecular Diagnostics?
HTG Molecular Diagnostics's major institutional shareholders are VANGUARD GROUP INC, UBS GROUP AG, TOWER RESEARCH CAPITAL LLC (TRC), BLACKROCK INC., and MORGAN STANLEY. The top five shareholders own together 2.65% of the company's share outstanding.
How many HTG Molecular Diagnostics shareholders are there?
As of Mar 2021, there are 1 institutional shareholders of HTG Molecular Diagnostics.
What percentage of HTG Molecular Diagnostics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC owns 14.69K shares of HTG Molecular Diagnostics, representing 1.65% of the company's total shares outstanding, valued at $39.67M (as of Mar 2023).
What percentage of HTG Molecular Diagnostics is owned by UBS GROUP AG?
As of Mar 2023, UBS GROUP AG holds 5.2K shares of HTG Molecular Diagnostics (HTGM), compromising 0.58% of the company, valued at $14.03M.
What percentage of HTG Molecular Diagnostics is owned by TOWER RESEARCH CAPITAL LLC (TRC)?
TOWER RESEARCH CAPITAL LLC (TRC) is the third largest holder of HTG Molecular Diagnostics. The company owns 1.48K of the company's shares outstanding (worth $4K).